

Disclosures

Personal Commercial (5)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Antag Pharma	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP
argenx BV	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP
Elsevier	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP
Lumia Health	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP
Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	Arrhythmias and Clinical EP

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (5)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Canadian Cardiovascular Society † I am on the Board	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	General Cardiology
Dysautonomia International † Non-profit patient advocacy group	Research/Research Grants ‡ -LDN for POTS RCT; Ivabradine vs Propranolol Comparative Effectiveness study; CMR in POTS study	Significant (>= \$5,000)	Arrhythmias and Clinical EP
Heart and Stroke Foundation of Canada † Not commercial; Foundation Peer Reviewed Grant	Research/Research Grants	Significant (>= \$5,000)	Arrhythmias and Clinical EP
Long COVID Web † CIHR funded research network	Research/Research Grants ‡ Effect of Volume Expansion on Cognitive Impairment in Long COVID	Significant (>= \$5,000)	Arrhythmias and Clinical EP
Standing Up to POTS † Non-profit patient advocacy group	Research/Research Grants ‡ Effect of Hyperventilation on Tachycardia in POTS	Significant (>= \$5,000)	Arrhythmias and Clinical EP

Clinical Trial Enroller (3)

Trial Name	Trial Sponsor	Trial Funding Source
Product Surveillance Registry	MEDTRONIC	
PHASE 2 DB PC SINGLE-DOSE STUDY OF PD, PK, SAFETY, AND TOLERABILITY OF REGN7544, AN NPR1 ANTAGONIST mAB, IN POTS	Regeneron	
Phase 3 Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure	Theravance, Inc.	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2026	Did motor vehicle accident contribute to POTS Symptoms	Plaintiff	Injury post MVA; rules to collect from auto insurance requires a lawsuit	Modest (< \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 1/28/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 1/28/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 1/28/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.